 |
0 Diseases |  |
3 Trials |
|
3 Trials |  |
224 News |  |
| «123 |
- ALKS 4230 / Alkermes, Keytruda (pembrolizumab) / Merck (MSD)
ARTISTRY-2: a phase 1/2 study of subcutaneously administrated ALKS 4230 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_802;
P1, P1/2
N/A
- ||| nemvaleukin alfa (ALKS 4230) / Mural Oncology
Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: ARTISTRY-1: A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors (clinicaltrials.gov) - Jun 4, 2019
P1/2, N=300, Recruiting, Sponsor: Alkermes, Inc.
N/A Phase classification: P1 --> P1/2 | N=150 --> 300 | Trial completion date: Jun 2020 --> Sep 2021 | Trial primary completion date: Jun 2020 --> Sep 2021
- ||| nemvaleukin alfa (ALKS 4230) / Mural Oncology
New P1 trial, Combination therapy, Monotherapy, Metastases: A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) (clinicaltrials.gov) - Mar 4, 2019
P1, N=230, Recruiting, Sponsor: Alkermes, Inc.
- | nemvaleukin alfa (ALKS 4230) / Mural Oncology
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: ARTISTRY-1: A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors (clinicaltrials.gov) - Jul 27, 2018
P1, N=150, Recruiting, Sponsor: Alkermes, Inc.
Phase classification: P1 --> P1/2 | N=150 --> 300 | Trial completion date: Jun 2020 --> Sep 2021 | Trial primary completion date: Jun 2020 --> Sep 2021 Trial completion date: Dec 2019 --> Jun 2020 | Trial primary completion date: Dec 2019 --> Jun 2020
- || nemvaleukin alfa (ALKS 4230) / Mural Oncology
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: ARTISTRY-1: A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors (clinicaltrials.gov) - Feb 6, 2018
P1, N=130, Recruiting, Sponsor: Alkermes, Inc.
Trial completion date: Dec 2019 --> Jun 2020 | Trial primary completion date: Dec 2019 --> Jun 2020 Trial primary completion date: Jun 2018 --> Dec 2019 | Trial completion date: Jun 2018 --> Dec 2019
- ||| nemvaleukin alfa (ALKS 4230) / Mural Oncology
Enrollment open, Combination therapy, Monotherapy, Metastases: ARTISTRY-1: A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors (clinicaltrials.gov) - Jul 25, 2016
P1, N=120, Recruiting, Sponsor: Alkermes, Inc.
Trial primary completion date: Jun 2018 --> Dec 2019 | Trial completion date: Jun 2018 --> Dec 2019 Not yet recruiting --> Recruiting
- ||| nemvaleukin alfa (ALKS 4230) / Mural Oncology
New P1 trial, Combination therapy, Monotherapy, Metastases: ARTISTRY-1: A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors (clinicaltrials.gov) - Jun 15, 2016
P1, N=120, Not yet recruiting, Sponsor: Alkermes, Inc.